Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 1;63(2):245-8.
doi: 10.1097/QAI.0b013e31828decf8.

Effect of the levonorgestrel intrauterine device on genital HIV-1 RNA shedding among HIV-1-infected women not taking antiretroviral therapy in Nairobi, Kenya

Jenell S Coleman  1 , Christina Mwachari, Jennifer Balkus, Lucy Sanguli, Angela Muliro, Kathy Agnew, Robert W Coombs, Craig R Cohen, Jane Hitti
Affiliations

Effect of the levonorgestrel intrauterine device on genital HIV-1 RNA shedding among HIV-1-infected women not taking antiretroviral therapy in Nairobi, Kenya

Jenell S Coleman et al. J Acquir Immune Defic Syndr. .

Abstract

The effect of the levonorgestrel-releasing intrauterine device (LNG-IUD) on genital HIV-1 RNA shedding and inflammation among 25 HIV-infected women was evaluated. Blood, endocervical, and cervicovaginal lavage samples were collected from HIV-infected women not taking antiretrovirals before LNG-IUD insertion and 1 month, 3 month, and 6 months thereafter. HIV-1 RNA was quantitated by real-time reverse transcriptase-polymerase chain reaction. Inflammatory markers were measured by enzyme immunoassay. Genital HIV-1 RNA shedding and inflammatory markers did not differ between LNG-IUD placement and month 6, with the exception of interleukin 1β that increased (0.42 log10; 95% confidence interval: 0.10 to 0.75). The LNG-IUD did not increase genital HIV-1 RNA shedding after 6 months of use.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No conflicts declared.

Figures

Figure 1
Figure 1
Study Population
See this image and copyright information in PMC

References

    1. World Health Organization. PMTCT strategic vision 2010–2015: prevention mother-to-child transmission of HIV to reach the UNGASS and Milennium Development Goals. Vol. 2010 Switzerland: 2010. Feb 2,
    1. Luukkainen T, Toivonen J. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Contraception. 1995;52:269–76. - PubMed
    1. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception. 1994;49:56–72. - PubMed
    1. Kaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2009;113:1104–16. - PubMed
    1. World Health Organization. Medical eligibility criteria for contraceptive use. Switzerland: 2009. - PubMed

Publication types